Remdesivir

Remdesivir Not A Ray of Hope Anymore

  • Gilead Sciences Inc.’s remdesivir is ineffective in treating hospitalized Covid-19 patients.
  • It was among the drugs President Donald Trump received when he was diagnosed with the disease in early October.

In The BMJ medical journal a panel of WHO-convened experts developing Covid-19 treatment guidelines said“There is currently no evidence that it improves survival or the need for ventilation”, says an article published in Bloomberg.

Negative Impacts on Gilead Sciences Inc.’s

Gilead shares fell...

https://mfame.guru/remdesivir-not-a-ray-of-hope-anymore/

Remdesivir Suffers Huge Blow After WHO Recommends Against Its Usage

The World Health Organizationrecommended against using Gilead Sciences Inc.’s remdesivir to treat hospitalized Covid-19 patients less than a month after U.S. regulators granted the drug a speedy approval, reports Bloomberg.

Huge blow to the drug

“There is currently no evidence that it improves survival or the need for ventilation,” a panel of WHO-convened experts developing Covid-19 treatment guidelines said in The BMJ medical journal.

The recommendation is a blow to Gilead’s drug, which was one...

https://mfame.guru/remdesivir-suffers-huge-blow-after-who-recommends-against-its-usage/

Scientists Question FDA Remdesivir Approval

  • Scientists have questioned FDA’s emergency authorization of GiLead’s Remdesivir overlooking critical data and evidence.
  • Many have questioned how the company has undermined WHO’s Solidarity trial.
  • The absence of viral load data in FDA’s approval evidence is a critical concern.
  • Scientists say an outside expert panel debate was necessary before the approval
  • Many are comparing this to the authorization of hydroxychloroquine use.

Within a month of publishing clinical trials data showing the effect...

https://mfame.guru/scientists-question-fda-remdesivir-approval/

The Dubious Case of Remdesivir, The First FDA Approved COVID Drug

  • Within weeks of Remdesivir trial data publishing, GiLead signed a EU manufacturing deal and got the drug approved by FDA.
  • The dubious circumstances of the first FDA approved covid drug shows how the company exploited and gained advantage.
  • Breaches and badmouthing of WHO’s solidarity trial is a noted problem
  • Added to this the lack of inclusion of critical study evidences and the absence of any outer panel expert debate for approval makes the matter dubious.

October was a good month for Gilead...

https://mfame.guru/the-dubious-case-of-remdesivir-the-first-fda-approved-covid-drug/

WHO Solidarity Trial Shows No Effective COVID Treatment

According to a Science Magazine report, one of the world’s biggest trials of COVID-19 therapies released its long-awaited interim results yesterday—and they’re a letdown.

No Effective Treatment

None of the four treatments in the Solidarity trial, which enrolled more than 11,000 patients in 400 hospitals around the globe, increased survival—not even the much-touted antiviral drug remdesivir. Scientists at the World Health Organization (WHO) released the data as a preprint on medRxiv last night,...

https://mfame.guru/who-solidarity-trial-shows-no-effective-covid-treatment/

US President’s COVID Treatment Protocol Shows the ‘Effective Line of Treatment’

After a successful covid19 treatment at the hospital, the US President has now returned home but the urgency in knowing how his covid19 illness was treated is gaining momentum. So, here’s a detailed insight into as given by an article published in Science.

The Line of Treatment
  • On 2 October, the White House announced President Donald Trump received an experimental antibody treatment after a test revealed he’s infected with SARS-CoV-2.
  • At the time, he reportedly had mild COVID-19 symptoms,...

https://mfame.guru/us-presidents-covid-treatment-protocol-shows-the-effective-line-of-treatment/

AI Drug Development Strategies Speed Up COVID Drug Manufacturing

An employee checks Arbidol capsules as they move along the production line at OAO Pharmstandard’s Leksredstva drug manufacturing unit in Kursk, Russia, on Friday, Aug. 16, 2013. Pharmstandard said it will offer $590 million in cash and shares for Bever Pharmaceutical Pte. Ltd. in a deal that will give Pharmstandard board member Alexander Shuster an 18.7 percent stake in Russia’s biggest drugmaker. Photographer: Andrey Rudakov/Bloomberg via Getty Images
  • As the pandemic medicines are unleashed...

https://mfame.guru/ai-drug-development-strategies-speed-up-covid-drug-manufacturing/

Lab Designed COVID19 Antibodies Better Than Remdesivir

According to an article published in Science, while the world is transfixed by the high-stakes race to develop a COVID-19 vaccine, an equally crucial competition is heating up to produce targeted antibodies that could provide an instant immunity boost against the virus.

Targeted monoclonal anitbodies

Clinical trials of these monoclonal antibodies, which could both prevent and treat the disease, are already underway and could produce signs of efficacy in the next few months, perhaps ahead of...

https://mfame.guru/lab-designed-covid19-antibodies-better-than-remdesivir/

World’s First Virtual International COVID19 Conference Shows New Cure

BREDA, NETHERLANDS – 2020/03/23: Paramedics move a patient on a stretcher to be transferred to another hospital due to overload amid Coronavirus outbreak.
The capacity of Brabant hospitals, including intensive care, will be insufficient in the coming week. Due to overload, approximately 500 to 700 patients will have to be taken to intensive care and other departments in hospitals outside the province, Marcel Visser reported on behalf of the Regional Consultation Acute Care Chain in Brabant in a...

https://mfame.guru/worlds-first-virtual-international-covid19-conference-shows-new-cure/

Low Cost Remdesivir Manufacturing License, $64 for 100mg

According to a Reuters report, Mylan NV (MYL.O) said on Monday that they are launching a generic version of Gilead Sciences Inc’s (GILD.O) COVID-19 antiviral remdesivir in India at 4,800 rupees ($64.31), about 80% below the price tag on the drug for wealthy nations.

Why this move?

California-based Gilead has signed licensing deals with several generic drugmakers in an effort to make remdesivir available in 127 developing countries.

Last month, two Indian drugmakers, Cipla Ltd (CIPL.NS) and...

https://mfame.guru/low-cost-remdesivir-manufacturing-license-64-for-100mg/

+ More
Join Our Newsletter
Enter your email to receive a weekly round-up of shipping news.
icon
By subscribing, you agree with our privacy policy and our terms of service.